Phoenix, MD, United States of America

John Tod Isaacs

USPTO Granted Patents = 21 


 

Average Co-Inventor Count = 2.8

ph-index = 9

Forward Citations = 222(Granted Patents)


Location History:

  • Baltimore, MD (US) (2001 - 2003)
  • Pheonix, MD (US) (2003 - 2014)
  • Phoenix, MD (US) (2001 - 2021)

Company Filing History:


Years Active: 2001-2021

Loading Chart...
Loading Chart...
Loading Chart...
21 patents (USPTO):Explore Patents

Title: John Tod Isaacs: Innovating Cancer Treatment Through Patented Technologies

Introduction

John Tod Isaacs is a prominent inventor based in Phoenix, MD, known for his significant contributions to the field of cancer treatment. With a remarkable portfolio of 21 patents, Isaacs has dedicated his career to developing innovative solutions aimed at improving cancer therapies and patient outcomes.

Latest Patents

One of Isaacs' latest inventions involves albumin-proaerolysin prodrugs, which specifically address cancer treatment. This invention presents compositions and methods designed to effectively treat cancer utilizing albumin-proaerolysin prodrugs. Notably, the prodrug composition includes a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), where a PSA cleavable linker replaces the native furin cleavage site within PA. The composition also incorporates human serum albumin (HSA) or a fragment fused to the N-terminus of the PSA-activated PA, showcasing Isaacs’ innovative approach to enhancing drug efficacy.

Career Highlights

Throughout his career, John Tod Isaacs has collaborated with renowned institutions such as The Johns Hopkins University and Genspera, Inc. His work in these esteemed organizations has provided a platform for advancing cancer research and patenting groundbreaking technologies. Isaacs’ dedication to innovation is evident in his extensive patent portfolio, which continues to grow as he explores new avenues for cancer treatment.

Collaborations

Isaacs has had the opportunity to collaborate with notable figures in his field, including Samuel Ray Denmeade and Hans Lilja. These collaborative efforts have enriched his research and fostered advancements in cancer therapies, further solidifying his reputation as a leading inventor in the industry.

Conclusion

John Tod Isaacs stands out as a visionary inventor in the realm of cancer treatment innovations. His contributions, as reflected in his 21 patents, demonstrate a commitment to leveraging scientific advancements for improved patient care. As his work continues to evolve, Isaacs remains a pivotal figure in the ongoing battle against cancer, dedicated to transforming the future of treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…